Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are manufactured by major pharmaceutical companies including Novo Nordisk, Eli Lilly, and Viking Therapeutics, with medications available through both brand-name and licensed compounded-pharmacy channels. As of 2024, compounded semaglutide and tirzepatide represent an accessible alternative pathway for patients seeking cost-effective access.

Selecting a GLP-1 medication involves more than choosing a manufacturer—it requires understanding regulatory pathways, cost structures, and individual physiological factors. PlexusDx emphasizes precision wellness by helping patients evaluate options through clinical evidence and, where appropriate, genetic context that may support more informed provider conversations.

Major Pharmaceutical Manufacturers and Their GLP-1 Portfolios

Novo Nordisk leads the GLP-1 market with semaglutide products: Ozempic (diabetes), Wegovy (weight management), and Rybelsus (oral form). The company maintains the largest market share and extensive clinical trial data supporting efficacy and safety profiles across diverse patient populations.

Eli Lilly produces tirzepatide (Mounjaro for diabetes, Zepbound for weight management) and dulaglutide (Trulicity). Lilly's dual GIP/GLP-1 receptor agonist mechanism represents a distinct pharmacological approach with comparable efficacy demonstrated in randomized controlled trials published in major medical journals.

Branded vs. Compounded GLP-1 Pathways: Regulatory and Access Differences

Branded GLP-1 medications undergo full FDA approval and carry standardized formulations. Compounded GLP-1 medications are prepared by licensed 503A pharmacies under pharmacy compounding regulations, offering flexibility in dosing and delivery but without formal FDA approval processes. Both pathways serve distinct patient needs and access situations.

Characteristic Branded GLP-1s Compounded GLP-1s
Manufacturer Major pharma (Novo Nordisk, Lilly, Viking) Licensed 503A compounding pharmacies
FDA Status FDA-approved formulations Pharmacy-compounded, not FDA-approved
Dosing Flexibility Fixed, standard doses Customizable doses and delivery
Cost Range $900–$1,400/month (typically) $129-$369/mo (varies by formulation)
Insurance Coverage Often covered; requires prior auth Limited insurance coverage; cash-pay common
Quality Standards GMP manufacturing; extensive QA USP <797> sterile compounding standards

Emerging Manufacturers and Novel GLP-1 Mechanisms

Viking Therapeutics is developing VK2735, a dual GIP/GLP-1 receptor agonist currently in late-stage trials, with data suggesting weight loss comparable to tirzepatide. Other companies including Structure Therapeutics and Viking are exploring oral formulations and novel receptor combinations to expand the therapeutic landscape.

Retatrutide, developed by Eli Lilly, represents a triple GIP/GLP-1/GCG receptor agonist in clinical development, showing enhanced weight loss in early studies. These emerging agents suggest the GLP-1 market will continue diversifying, offering patients and providers additional mechanism-based options for personalized treatment.

Genetic Biomarkers and Individual Response Variation: A Clinical Consideration

Response to GLP-1 medications varies substantially between individuals, in part due to genetic variation in peptide pathway genes. Key variants in GLP1R, GIPR, FTO, and MC4R influence appetite signaling, metabolic efficiency, and weight regulation—factors that may contextualize individual treatment response.

PlexusDx's Precision Peptide Genetic Test may help identify predispositions in these peptide pathways, providing context for provider conversations about medication selection. This test does not predict exact medication response but may support a more informed, individualized discussion about which GLP-1 approach aligns with a patient's physiological profile and clinical goals.

How to Evaluate Manufacturer and Formulation Options with Your Provider

When selecting a GLP-1 medication, discuss with your provider: mechanism of action (single vs. dual GIP/GLP-1), clinical evidence in your specific population, cost and insurance coverage, dosing flexibility needs, and any contraindications or comorbidities. This conversation should prioritize efficacy, safety, and personal access factors rather than manufacturer brand alone.

Compounded semaglutide and tirzepatide from licensed 503A pharmacies offer cost-effective alternatives when branded options are inaccessible. PlexusDx provides compounded options ranging from $129-$369/mo monthly, allowing providers and patients to optimize treatment within realistic budget constraints while maintaining quality and safety standards.

How PlexusDx Supports a More Personalized Approach

PlexusDx contextualizes GLP-1 manufacturer and formulation choices through precision-wellness principles. Our genetic testing in peptide pathway variants—GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—may help provide context about individual biological predispositions to GLP-1 response. This information should always be interpreted with a qualified healthcare provider.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in peptide signaling pathways relevant to appetite, metabolic regulation, and GLP-1 receptor function. These genetic insights do not predict exact medication response or guarantee outcomes but may support a more nuanced conversation about which GLP-1 approach aligns with your individual physiology.

Whether selecting a branded GLP-1 from a major manufacturer or exploring compounded options through PlexusDx, pairing this decision with genetic biomarker context can support a more informed provider conversation. Understanding both your manufacturer options and your individual genetic predispositions empowers more personalized, evidence-based treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves